VAREX IMAGING VREX
- Market cap
- $784.3M
- P/E
- 34.8×
Follow VREX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 25.00 | 21.57 | 22.73 | 10.37 | 16.60 | 18.90 | 17.05 | 10.19 | 6.76 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | 41.99 | 43.76 | 35.00 | 31.90 | 32.65 | 32.41 | 23.90 | 21.06 | 15.46 |
High Price
|
|||
| 1,400 | 2,000 | 2,000 | 2,000 | 2,000 | 2,100 | 2,300 | 2,400 | 2,300 | 2,400 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 620 | 698 | 773 | 781 | 738 | 818 | 859 | 893 | 811 | 845 |
Revenue
|
|||
| 40.06% | 36.31% | 32.83% | 32.88% | 25.76% | 33.19% | 32.99% | 32.49% | 31.68% | 34.39% |
Gross Margin
|
|||
| 105 | 75 | 26 | 22 | (73) | 29 | 45 | 31 | 5 | (59) |
EBT
|
|||
| 16.93% | 10.71% | 3.32% | 2.75% | (9.83%) | 3.50% | 5.18% | 3.50% | 0.62% | (7.01%) |
EBT Margin
|
|||
| 69 | 52 | 28 | 16 | (57) | 18 | 31 | 48 | (48) | (70) |
Net Income
|
|||
| 15 | 29 | 48 | 46 | 47 | 47 | 45 | 36 | 34 | 124 |
Depreciation
|
|||
| 16.58 | 18.57 | 20.41 | 20.43 | 19.03 | 20.82 | 21.59 | 22.17 | 19.88 | 20.40 |
Revenue/Sh
|
|||
| 1.84 | 1.37 | 0.73 | 0.43 | (1.47) | 0.44 | 0.76 | 1.20 | (1.17) | (1.70) |
Earnings/Sh
|
|||
| 1.98 | 2.00 | 2.25 | 1.88 | 0.34 | 2.36 | 0.42 | 2.69 | 1.16 | 1.01 |
Cash Flow/Sh
|
|||
| (0.77) | (0.54) | (0.54) | (0.52) | (0.61) | (0.38) | (0.54) | (0.51) | (0.66) | (0.55) |
Capex/Sh
|
|||
| 1.21 | 1.46 | 1.71 | 1.36 | (0.27) | 1.97 | (0.11) | 2.18 | 0.50 | 0.45 |
Free CF/Sh
|
|||
| 14.06 | 10.08 | 11.30 | 11.73 | 12.01 | 12.63 | 13.74 | 14.42 | 13.31 | 11.75 |
Book Value/Sh
|
|||
| 37 | 38 | 38 | 38 | 39 | 39 | 40 | 40 | 41 | 41 |
Shares
|
|||
| 12.59 | 24.83 | 38.23 | 66.37 | 0.00 | 62.67 | 27.45 | 15.50 | 0.00 | 0.00 |
PE Ratio
|
|||
| 1.60 | 1.84 | 1.37 | 1.40 | 0.67 | 1.35 | 0.98 | 0.84 | 0.60 | 0.61 |
PS Ratio
|
|||
| 1.82 | 3.40 | 2.47 | 2.43 | 1.06 | 2.23 | 1.54 | 1.29 | 0.90 | 1.06 |
PB Ratio
|
|||
| 1.52 | 2.42 | 1.80 | 1.86 | 1.15 | 1.71 | 1.36 | 1.12 | 0.90 | 0.86 |
EV/Sales
|
|||
| 14.96 | 30.70 | 21.51 | 27.94 | (82.35) | 18.04 | (265.08) | 11.38 | 35.75 | 38.60 |
EV/FCF
|
|||
| 74 | 75 | 85 | 72 | 13 | 93 | 17 | 108 | 47 | 42 |
Op' Cash Flow
|
|||
| (29) | (20) | (20) | (20) | (23) | (15) | (21) | (21) | (27) | (23) |
Capex
|
|||
| 45 | 55 | 65 | 52 | (10) | 78 | (4) | 88 | 20 | 19 |
FCF
|
|||
| 282 | 344 | 306 | 263 | 361 | 388 | 437 | 496 | 454 | 455 |
Working Cap'
|
|||
| — | 484 | 390 | 395 | 455 | 435 | 414 | 443 | 443 | 368 |
Total Debt
|
|||
| (36) | 401 | 338 | 365 | 355 | 290 | 325 | 249 | 243 | 212 |
Net Debt
|
|||
| 526 | 379 | 428 | 448 | 466 | 497 | 547 | 581 | 543 | 487 |
Sh' Equity
|
|||
| 11.36% | 6.21% | 2.71% | 1.53% | (5.32%) | 1.52% | 2.60% | 3.89% | (3.96%) | (6.06%) |
ROA
|
|||
| 13.93% | 6.71% | 3.63% | 3.51% | (2.57%) | 5.89% | 6.32% | 5.81% | 2.55% | (2.49%) |
ROIC
|
|||
| 13.41% | 11.40% | 6.81% | 3.54% | (12.67%) | 3.62% | 5.81% | 8.41% | (8.68%) | (13.65%) |
ROE
|
|||
VAREX IMAGING peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AHCO AdaptHealth Corp. | $756.7M | 0.0× | Compare |
| INMD InMode Ltd. | $815.7M | 11.4× | Compare |
| CTKB Cytek Biosciences, Inc. | $744.8M | 0.0× | Compare |
| SIBN SiBone | $830.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QDEL QuidelOrtho Corporation | $733.1M | 0.0× | Compare |
| CBLL CeriBell, Inc. | $914.2M | 0.0× | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $949.2M | 0.0× | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | 0.0× | Compare |
VAREX IMAGING (VREX) key facts
- VAREX IMAGING (VREX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- VAREX IMAGING’s revenue for fiscal 2025 (year ended September 2025) was $844.6 million, up 4.14% from fiscal 2024.
- VAREX IMAGING reported a net loss of $69.9 million, or a loss of $1.70 per share, for fiscal 2025.
- As of September 25, 2026, VREX traded at $18.45, a market capitalization of $784.3 million.
- At that price the stock trades at 34.8× trailing-twelve-month earnings and 0.9× sales.
- Return on equity was −13.7% and debt-to-equity 0.68.
VAREX IMAGING (VREX) Latest News
26 Aug
Varex Imaging (VREX) shares surged 50% after Teledyne (TDY) announced a buyout deal, coinciding with advancing turnaround momentum at the company. Acquisition by Teledyne fundamentally redefines Varex Imaging's competitive position and long-term prospects.
14 Aug
Teledyne Technologies acquires Varex Imaging at a 52% premium. Acquisition at 52% premium ends Varex independent operations and resets its valuation.
12 Aug
Teledyne Technologies (TDY) agrees to $1.1 billion imaging deal to expand X-ray capabilities involving Varex Imaging (VREX). Acquisition by Teledyne Technologies for $1.1 billion fundamentally changes Varex Imaging ownership and trajectory.
11 Aug
Teledyne agrees to acquire Varex Imaging for $1.1bn. The $1.1bn acquisition ends Varex Imaging's standalone operations and resets its market trajectory.
Teledyne signs $1.1B deal to acquire Varex Imaging. $1.1B takeover ends Varex independence and folds operations into Teledyne.
10 Aug
Teledyne Technologies will acquire Varex Imaging for $1.1 billion. The $1.1 billion acquisition ends Varex Imaging's independence and resets its competitive position under new ownership.
Teledyne acquires Varex Imaging in a $1.1 billion deal. The $1.1 billion acquisition by Teledyne fundamentally redefines Varex Imaging ownership and long-term trajectory.
Teledyne announced the acquisition of Varex Imaging Corporation. Acquisition by Teledyne will fundamentally alter Varex Imaging's ownership structure and long-term market trajectory.
Varex Imaging enters a $1.1 billion deal, sending its stock price surging 48%. A $1.1 billion deal directly drives a 48% stock surge for Varex Imaging.
Varex reported Q3 FY2026 revenue growth and margin expansion ahead of Teledyne transaction. Revenue growth and margin expansion ahead of Teledyne transaction point to major strategic impact on Varex trajectory.
Varex Imaging (VREX) released financial results for its third quarter of fiscal year 2026. Quarterly earnings releases directly affect investor sentiment and near-term stock valuation for Varex Imaging.
VAREX IMAGING (VREX) Q3 earnings beat estimates. Q3 earnings beat can influence near-term stock performance and sentiment without fundamentally changing company trajectory.
VAREX IMAGING shares jumped after the company announced stronger-than-expected quarterly results and raised full-year guidance, citing higher demand for its X-ray imaging components and improved supply-chain conditions. Raised guidance and higher component demand point to improved near-term revenue but do not signal a fundamental shift in competitive position or long-term trajectory.
11 May
Varex Imaging Corporation missed earnings expectations with a surprise loss. Analysts have issued their latest forecasts. Earnings miss and surprise loss moderately impact financial performance and investor sentiment.
9 May
Varex Imaging released Q2 earnings call highlights detailing quarterly financial results, operational updates, and forward-looking guidance. Q2 earnings highlights directly influence financial performance metrics and investor expectations for future growth.
8 May
Varex Imaging (VREX) released its Q2 2026 earnings call transcript detailing financial results, performance, and forward guidance. Q2 2026 earnings transcript discloses key financial metrics, operational updates, and outlook that could significantly sway investor sentiment and stock trajectory.
Varex Imaging Corporation released its Q2 2026 earnings call summary, detailing quarterly financial results, operational performance, strategic updates, and future outlook. Quarterly earnings summaries provide critical financial metrics and guidance that significantly shape investor sentiment and stock trajectory.
7 May
Varex Imaging announced financial results for second quarter fiscal year 2026. Quarterly earnings announcements significantly impact stock performance and investor sentiment.
Varex Imaging (VREX) Q2 earnings compared to analyst estimates, with analysis of key metrics. Q2 earnings versus estimates moderately influences VREX financial performance and market sentiment.
Varex Imaging (VREX) Q2 earnings and revenues missed analyst estimates. Q2 earnings and revenue misses highlight underperformance that could moderately affect financial results and investor sentiment.
30 Apr
Wall Street analysts predict VAREX IMAGING (VREX) stock could surge 63.19%, urging investors to review details before betting. Analyst forecasts of 63.19% upside signal moderately positive sentiment shift for VREX market performance.
14 Apr
Varex Imaging (VREX) upgraded to Strong Buy rating by analysts due to favorable outlook on growth, financials, and market position. Analyst upgrade to Strong Buy expected to moderately boost investor sentiment and short-term stock performance.
Wall Street analysts forecast a 57.62% upside for Varex Imaging (VREX) stock, questioning whether it can realistically achieve this target. Analyst price targets signal moderate potential to influence investor sentiment and stock trajectory amid scrutiny of attainability.
11 Apr
Varex Imaging (VREX) investment story shifts amid new risk assessments and revised earnings assumptions. New risks and earnings assumptions indicate significant changes to VREX's trajectory and market sentiment.
22 Mar
Varex Imaging reports steady demand despite geopolitical tensions. Tariff relief expected to improve margins. India market ramp-up ahead. Tariff relief lifts margins and India expansion signals growth opportunities.
Varex Imaging CFO at conference highlights company's ability to pass through tariffs to customers, expansion of factories in India, growth opportunities in cargo screening systems, and progress in photon-counting detector technology. Tariff pass-through capability, India factory expansions, cargo systems growth, and photon-counting advancements represent major strategic moves enhancing resilience, diversification, and innovation.
16 Mar
Varex Imaging announces successful completion of debt refinancing. Debt refinancing strengthens financial position, reduces interest expenses, and boosts investor confidence.
6 Mar
Varex Imaging Corporation announces redemption of its 7.875% Senior Secured Notes due 2027. Redeeming senior secured notes ahead of maturity reduces debt obligations and impacts financial health moderately.
13 Feb
Varex Imaging Corporation's share price has shown fluctuations recently, reflecting broader market trends and investor sentiment. Analysts are closely monitoring the company's performance, particularly in light of recent developments in the imaging sector. The company's strategic initiatives and product innovations are expected to play a crucial role in shaping its future market position. Recent developments may moderately influence Varex Imaging's financial performance and competitive positioning.
11 Feb
Varex Imaging Corporation reported its Q1 2026 earnings, highlighting a revenue increase driven by strong demand for its imaging products. The company noted improvements in operational efficiency and cost management, which contributed to a rise in net income. Management expressed optimism about future growth prospects, citing ongoing investments in innovation and expansion into new markets. Challenges such as supply chain disruptions and competitive pressures were acknowledged, but the overall outlook remained positive as Varex aims to enhance its product offerings and market presence. The earnings report indicates significant operational improvements and strategic investments that could alter the company's growth trajectory.